3D Bioprinting Market by Product (Bioprinter [Extrusion, Laser, SLA, FDM, SLS], Bioinks, Materials [Hydrogels, Cells, Biomaterials], Software, Accessories) Application (Cancer Research, Tissue Engineering, Drug Discovery) End User - Global Forecast to 2030

3D Bioprinting Market

The 3D Bioprinting Market is projected to reach $5.21 billion by 2030, at a CAGR of 17.1% from 2024 to 2030. 3D Bioprinting is a technique that employs biomaterials and cells compared to traditional polymers and metals to generate functional 3D tissues. The 3D Bioprinting incorporates pre-bioprinting, bioprinting, and post-bioprinting. This technology is employed in various research areas, such as regenerative medicines, cancer research, tissue engineering, and many others. Numerous bioprinting techniques have been developed, such as inkjet printheads, laser-induced methods, acoustic wave methods, applied pressure, and solenoid valve-based methods, to deposit cells onto substrates. The preference for 3D bioprinting is growing compared to conventional bioprinting techniques due to its ability to digitally define tissue constructs and reproduce complex 3D structures using automated processes, achieving resolutions not feasible with traditional methods.

The growth of this market is driven by factors such as technological advancements in 3D bioprinting, the rising geriatric population coupled with the growing burden of chronic diseases, and increasing R&D investments. Additionally, the increasing demand for organ transplantation is expected to offer significant market growth opportunities.

However, the lack of skilled professionals and the high costs associated with 3D bioprinting restrain the growth of this market. Additionally, concerns regarding intellectual property rights and safety issues associated with the use of 3D bioprinted products are some of the challenges impeding the market's growth.

The Rising Geriatric Population, Coupled with the Growing Burden of Chronic Diseases, is Driving the Market’s Growth

There has been a continuous rise in the geriatric population due to rising life expectancy, improved healthcare quality, urbanization, and growing income levels, leading to greater survival rates. According to the United Nations, there were 727 million people aged 65 years or over globally in 2020. The global share of the aged population (65 years or over) is expected to increase from 9.3% (727 million) in 2020 to 16.0% (1,548.9 million) in 2050, i.e., one in four persons living in Europe and North America could be aged 65 years or over. This remarkable growth in the geriatric population is also driven by declining fertility rates and improvements in longevity.

Additionally, with the rapid growth in the global geriatric population, cases of age-related chronic diseases are expected to increase globally. This demographic shift is leading to the increased prevalence of various chronic diseases. According to the Centers for Disease Control and Prevention (CDC), in 2022, six in ten people in the U.S. had at least one chronic disease, such as cardiovascular disease, cancer, and diabetes. Furthermore, according to the GLOBOCAN, in 2020, 19.3 million cancer cases were diagnosed all over the world. It is expected to increase up to 24.5 million by 2030.

Thus, the increasing geriatric population, coupled with the growing burden of chronic diseases, drives the 3D bioprinting market.

Click here to: Get Free Sample Pages of this Report

Increasing Demand for Organ Transplantation to Offer Market Growth Opportunities

Over the past decade, there has been a significant increase in the demand for organ transplantation. This growth in demand can be attributed to factors such as the rising incidence of organ failure, the high success rate of transplant procedures, and improved post-transplant outcomes. Metabolic diseases, including diabetes, high blood pressure, heart disease, and metabolic syndrome, are the primary causes of organ failure. The prevalence of these diseases has contributed to a higher number of organ transplant cases.

According to the Health Resources and Services Administration (HRSA), in 2022, 1 million organs were transplanted worldwide, out of which 104,234 women, men, and children were on the waiting list. Liver transplantation is necessary when the liver fails due to various reasons, including alcoholic liver disease, hepatitis, metabolic diseases, and other liver diseases. According to GLOBOCAN, 905,677 cases of liver cancer were detected in 2020. This number is projected to increase to 1.2 million by 2030. The rising incidence of liver cancer underscores the need for liver transplantation. 3D bioprinting enables the generation of bioengineered liver organoids and tissues from patients' own cells, reducing the possibility of rejection and eliminating the requirement for immunosuppressive drugs, which are frequently required after conventional organ transplantation.

Key Findings in the 3D Bioprinting Market Study:

Among the Products, the Bioprinters Segment is Expected to Account for the Largest Share of the Market in 2024

Among the products, in 2024, the bioprinters segment is expected to account for the largest share of the 3D bioprinting market. 3D bioprinters produce tissues and organ patches using a patient's own cells, which can reduce the risk of rejection, enable personalized treatments, and decrease reliance on animal testing. Additionally, technological advancements in 3D bioprinters have enabled researchers to explore diverse applications and streamline the development process. These factors contribute to the large market share of this segment.

Among the Applications, the Cancer Research Segment is Expected to Account for the Largest Share of the Market in 2024

Among the applications, in 2024, the cancer research segment is expected to account for the largest share of the 3D bioprinting market. The large market share of this segment is attributed to the rising prevalence of cancer. According to GLOBOCAN, in 2020, 19.3 million cancer cases were diagnosed all over the world. The number of cases is expected to increase to 24.5 million by 2030. Cancer models that replicate the tumor microenvironment are produced using 3D bioprinting, assisting researchers with cancer medication screening and contributing to a greater understanding of cancer.

Among the End Users, the Pharmaceutical and Biotechnology Companies Segment is Expected to Account for the Largest Share of the Market in 2024

Among the end users, in 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the 3D bioprinting market. The large market share of this segment is attributed to rising collaborations between pharmaceutical companies and 3D bioprinting providers to reduce global organ shortages. For Instance, in September 2020, CollPlant Biotechnologies (Israel) collaborated with United Therapeutics Corporation (U.S.) to reduce global organ shortages of kidney transplants and save the lives of millions of patients on kidney waiting lists.

Asia-Pacific: Fastest-growing Regional Market

The market in Asia-Pacific is projected to register the highest CAGR during the forecast period. The growth of this regional market is attributed to the increasing incidence of cancer, the presence of key 3D bioprinting companies in countries like China, India, Singapore, and Japan, advancements in 3D bioprinting technology such as improved vascularization of printed tissues, and government investments in research and development activities.

3D Bioprinting Market : Key Companies

The report offers a competitive landscape based on an extensive assessment of the offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past three to four years. The key players profiled in the 3D bioprinting market report are Organovo Holdings Inc. (U.S.), BICO Group AB (Sweden), Aspect Biosystems Ltd. (Canada), Cyfuse Biomedical K.K. (Japan), Advanced Solutions Life Sciences, LLC (U.S.), CollPlant Biotechnologies Ltd. (Israel), regenHU Ltd. (Switzerland), Poietis (France), REGEMAT 3D, SL (Spain), 3DBio Therapeutics (U.S.), and Foldink Life Science Technologies (Armenia).

3D Bioprinting Market Report Summary:

Key questions answered in the 3D Bioprinting Market report: